Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>JPM Keeps MEDBOT-B as Top Pick in CN Medical Tech Sector, But Tweaks Down TP to HKD41
Recommend 1 Positive 1 Negative 0 |
||||
|
||||
|
According to JPMorgan's research report, the preliminary FY25 results forecast for MEDBOT-B (02252.HK) exceeded market expectations but fell short of the broker's estimates. JPMorgan has tweaked down its target price for MEDBOT-B from HKD42 to HKD41, with a rating of Overweight. MEDBOT-B remains the broker's top pick in China's medical technology sector. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
